CFDA Reviews Spate Of J&J Product Recalls, Seeks Quality Commitments
This article was originally published in PharmAsia News
Executive Summary
China FDA officials recently met with executives of Johnson & Johnson to review a spate of product recalls in China since 2009, with requesting the company to identify and rectify quality management system flaws by instituting risk control measures and adhering to Chinese laws and technical standards.